• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Brodalumab may be effective for difficult-to-treat psoriasis

byShirin BajajandAdam Whittington
January 3, 2015
in Chronic Disease, Dermatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with brodalumab was shown to be safe and efficacious in patients with psoriatic arthritis or who previously failed treatment with biologic therapy. 

Evidence Rating Level: 2 (Good)

Study Rundown: Psoriasis is a chronic inflammatory skin disease that classically presents with itchy red lesions with a silvery scale. A difficult-to-treat subgroup of these patients, those with a history of psoriatic arthritis (PsA) or those who have failed biologic therapy, necessitate more treatment options. These authors performed a secondary analysis on the safety and efficacy of brodalumab, a novel therapy previously shown to improve psoriatic outcomes, in a difficult-to-treat cohort. When comparing patients with or without history of biologic use and patients with or without self-reported PsA, there were similar improvements in outcome and quality of life as compared to those treated with a placebo, indicating the utility of the therapy even for patients classically considered to have difficult-to-treat disease. While the randomized-controlled double-blind, placebo-controlled design is inherently strong, the study had notable limitations: (1) the differences between the subgroups were not compared statistically, (2) history of psoriatic arthritis was self-reported, and (3) information regarding reason for discontinuation of biologic therapy was not collected.

Click to read the study in JAAD

Relevant Reading: Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies

In-Depth [randomized controlled trial]: Four separate measures assessing quality of life and psoriasis severity were used to evaluate the two subsets of patients with moderate-severe difficult-to-treat plaque psoriasis [(1) those with or without PsA and (2) with or without history of biologic use]. Among the sub-groups, the mean duration of psoriasis ranged from 17.3 years to 24.3 years. Within all sub-groups, there were similar trends of 75%, 90%, and 100% improvement at 12 weeks when compared to baseline using the Psoriasis Area and Severity Index score (PASI) in those that received either 140 mg or 210 mg of medication as compared to those that received placebo with one exception. In the 140 mg group, the percentage of patients with 100% improvement was observed to be higher in patients with a history of PsA. Analyzing the sub-groups using the Dermatology Life Quality Index (DLQI), Psoriasis Symptom Inventory (PSI) and Physician Global Assessment Scales (PGA) demonstrated similar results. The amount of adverse events in patients who received brodalumab as compare to placebo was comparable amongst all subgroups.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 35

#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms

Interleukin-23 receptor antagonist improves psoriasis symptoms

More from this author: Tech-aided surveillance of patients at high risk for melanoma aids early diagnosis, Indoor tanning linked to high skin cancer risk in US and abroad, Free drug samples may alter prescription habits of dermatologists, Atopic dermatitis may be more persistent than previously understood

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: Brodalumabpsoriasis
Previous Post

No benefit of erlotinib in combined hepatocellular carcinoma treatment

Next Post

Similar outcomes after supracervical vs. total hysterectomy

RelatedReports

The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 35

February 22, 2024
#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms
StudyGraphics

#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms

February 22, 2024
Severe psoriasis linked with poorly controlled blood pressure
Chronic Disease

Interleukin-23 receptor antagonist improves psoriasis symptoms

February 15, 2024
Anti-IL-17A therapy linked to sustained improvement in plaque psoriasis: The UNCOVER trials
Chronic Disease

Spesolimab may improve quality of life in patients with generalized pustular psoriasis flares

November 14, 2023
Next Post
Similar outcomes after supracervical vs. total hysterectomy

Similar outcomes after supracervical vs. total hysterectomy

Venous thromboembolism after vaginal delivery rising, preventative measures lacking

No benefit to antibiotics for term rupture of membranes

Small screen exposure associated with decreased sleep duration, quality

Small screen exposure associated with decreased sleep duration, quality

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.